帕金森病是一种中老年常见的神经系统退行性疾病，非麦角类罗匹尼罗为代表的多巴胺受体（DR）激动剂为治疗首选药物。现行临床疗效指标如UPDRS评分等易受主观影响，临床需一种更为客观有效的疗效指标。而利用PET脑纹状体D2/3受体显像技术开展的DR占有率可使解决该问题成为可能。国外研究主要集中在DR抑制药，但由于技术原因DR激动药研究未见报道，而在我国DR占有率研究仍为空白。本课题组前期大鼠研究论证了该技术在罗匹尼罗DR占有率测定的可行性以及其与药物浓度的相关性。本研究旨在应用以18F-Fallypride为显像剂的PET脑显像技术探索猴体内罗匹尼罗的血药浓度与纹状体DR占有的相关性，建立PK/PD模型为临床提供罗匹尼罗安全有效的给药方案，并进一步探讨临床可能的治疗窗及其机制；并以此为基础建立运用显像技术开展DR占有率研究的技术平台。

Parkinson's disease is a nervous system degenerative disease in middle-aged and old people. Ropinirole, a non-ergoline dopamine agonist, has been selected as one of the preferred drug treatment by the guide. Unified Parkinson’s Disease Rating Scale (UPDRS) motor scores were used to assess clinical therapeutic effect, which is easily affected by the subjective factors of patients and doctors. Therefore, it is badly necessary to find a more objective therapeutic effect index. For treatment effect is proportional to the dopamine receptor (DR) occupancy, the best way to solve this problem is to study the therapeutic window, using PET cerebral imaging technology. Currently, foreign research mainly focus on DR antagonists, which are used for the treatment of neuropsychiatry. These studies certified that DR occupancy may be a subjective way to evaluate clinical therapeutic effect. However, there is no study about DR agonist to date, and even no study about DR occupancy in China. Our previous research demonstrates the feasibility of PET brain imaging technology in studying DR occupancy and association between the concentration and occupancy after ropinirole was administered. In consequence, using PET imaging technology, the association between DR occupancy and the concentration of ropinirole in monkey brain will be studied, and a PK/PD model will be built to privide a new therapeutic regimen, which will be much more safety and effective. In further, a possible DR occupancy therapeutic window in clinical and its mechanism will be found. And in all, a new platform to study DR occupancy of DR agonist will be investigated to Parkinson’s disease base on our study.